Compare Crispr Therapeutics AG (CRSP) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Wayfair Inc — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Wayfair Inc trades at $89 (market cap $11.71B). The key difference: Wayfair Inc is far larger — about 2.4× Crispr Therapeutics AG's market cap, and Wayfair Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | W | |
|---|---|---|
Market Cap | $4.97B | $11.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $119.05 |
52-Week Low | $44.34 | $53.37 |
Enterprise Value | $3.32B | $14.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Wayfair (W) trades at $86.37, down 3.21% today, with a bearish technical signal but strong analyst support. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company maintains revenue growth but operates at a net loss, with a negative net income margin of -2.41%. Positive sentiment is driven by expansion into brick-and-mortar stores and AI integration, as highlighted by Bloomberg on July 8, 2026.
The outlook is cautiously optimistic due to a 51.78% buy rating from analysts and a consensus price target of $92.64, offering potential upside. However, risks include persistent unprofitability, high debt-to-asset ratio of 95.11%, and competitive e-commerce pressures. Investors should weigh growth initiatives against financial sustainability amid macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
